This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

£200 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
4 - 6 June, 2024
Excel London Platinum Suite

Jeremy Myers, Ph.D.
Senior Vice President, R&D at EvolveImmune Therapeutics


Jeremy Myers is senior vice president at and EvolveImmune Therapeutics and leads EvolveImmune’s immunobiology and biotherapeutic research teams.

Before joining EvolveImmune, Jeremy helped lead Pfizer oncology research and development in Pearl River, NY as senior director and head of the Integrative Biotechnology Group which focused on novel drug target discovery through integrative omics, RNA interference and CRISPR-Cas9 based screening. During his tenure, Jeremy established various preclinical programs based on cell surface tumor antigen discoveries and led various aspects of the discovery and evaluation of tumor antigen targets in antibody-drug conjugates, T-cell retargeting bispecific biotherapeutics and novel targeted immunotherapy platforms created by his team.

Before Pfizer, Jeremy was a research faculty member and AstraZeneca Research Fellow in the Department of Biochemistry at Vanderbilt University Medical School. Jeremy received his bachelor’s degree in biology from Bucknell University. He completed doctorate studies in biochemistry and molecular biology at the LSU Health Sciences Center and Louisiana State University. He completed a postdoctoral fellowship at Vanderbilt University.

Agenda Sessions

  • EVOLVE: A Novel CD2 Costimulatory T Cell Engager Platform For Solid Tumors